{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=83",
    "query": {
      "intervention": "Capsule 2",
      "page": 83
    },
    "page_size": 10
  },
  "pagination": {
    "page": 83,
    "page_size": 10,
    "total_count": 5061,
    "total_pages": 507,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=84&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=82&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T01:45:49.441Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00297167",
      "title": "Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Exocrine Pancreatic Insufficiency"
      ],
      "interventions": [
        {
          "name": "EUR-1008 (APT-1008)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2006-05",
      "completion_date": "2006-11",
      "has_results": true,
      "last_update_posted_date": "2017-03-16",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 1,
      "location_summary": "Tyler, Texas",
      "locations": [
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00297167"
    },
    {
      "nct_id": "NCT00634010",
      "title": "Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Morphine",
          "type": "DRUG"
        },
        {
          "name": "Methadone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2008-02",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-05-09",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 3,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634010"
    },
    {
      "nct_id": "NCT03880123",
      "title": "Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liposarcoma",
        "Malignant Peripheral Nerve Sheath Tumors",
        "Alveolar Soft Part Sarcoma",
        "Ewing Sarcoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matthew Ingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-11",
      "completion_date": "2020-11-24",
      "has_results": false,
      "last_update_posted_date": "2020-11-27",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03880123"
    },
    {
      "nct_id": "NCT03893422",
      "title": "Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "WB-010",
          "type": "OTHER"
        },
        {
          "name": "WB-011",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Pendulum Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 76,
      "start_date": "2017-10-22",
      "completion_date": "2018-09-14",
      "has_results": false,
      "last_update_posted_date": "2020-02-27",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 5,
      "location_summary": "Torrance, California • Tustin, California • Youngstown, Ohio + 2 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Youngstown",
          "state": "Ohio"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03893422"
    },
    {
      "nct_id": "NCT02255422",
      "title": "RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MItochondrial Myopathies"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone capsules, 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 5 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 20 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 40 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 80 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 160 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 53,
      "start_date": "2015-05-05",
      "completion_date": "2017-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Akron, Ohio + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02255422"
    },
    {
      "nct_id": "NCT01185002",
      "title": "Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Colonoscopy",
        "Endoscopy"
      ],
      "interventions": [
        {
          "name": "PillCam® COLON 2 procedure using MgC boosts",
          "type": "OTHER"
        },
        {
          "name": "PillCam® COLON 2 procedure using Suprep boosts",
          "type": "OTHER"
        },
        {
          "name": "PillCam® COLON 2 procedure using reduced dose of Suprep boosts",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Medtronic - MITG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2010-07",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 7,
      "location_summary": "Huntsville, Alabama • Indianapolis, Indiana • New York, New York + 4 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Beavercreek",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01185002"
    },
    {
      "nct_id": "NCT01910402",
      "title": "A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir/abacavir/lamivudine FDC",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir/emtricitabine FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 499,
      "start_date": "2013-08-22",
      "completion_date": "2022-08-18",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01910402"
    },
    {
      "nct_id": "NCT05918627",
      "title": "A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Immune System Disorder (Healthy Volunteer)"
      ],
      "interventions": [
        {
          "name": "Belumosudil mesylate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kadmon, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2009-09-21",
      "completion_date": "2009-12-09",
      "has_results": false,
      "last_update_posted_date": "2023-06-26",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05918627"
    },
    {
      "nct_id": "NCT03204331",
      "title": "SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis Related Pain"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate placebo",
          "type": "DRUG"
        },
        {
          "name": "Relugolix placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 623,
      "start_date": "2017-11-01",
      "completion_date": "2021-05-31",
      "has_results": false,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 41,
      "location_summary": "Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03204331"
    },
    {
      "nct_id": "NCT03173170",
      "title": "A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "TAK-954",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-05-31",
      "completion_date": "2017-07-24",
      "has_results": true,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-11-14T01:45:49.441Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173170"
    }
  ]
}